Diagnostic Value of I-131 NP-59 SPECT/CT Scintigraphy in Patients with Subclinical or Atypical Features of Primary Aldosteronism

Table 2

Imaging and pathological data of study subjects.

Patient	Age (y)	Gender	CT result		NP-59 result			Pathological result		Followup improvement
			Appearance (side)	Size (mm)	Planar	SPECT	SPECT/CT	Finding	Size (mm)
Control group (n = 9)
1	50	F	Nodule (L)	20	—	—	—	Adenoma	21	PAC, PRA, K
2	34	F	Nodule (L)	18	—	—	—	Adenoma	16	PAC, PRA, K, BP
3	58	F	Nodule (R)	17	—	—	—	Adenoma	17	PAC, PRA, K
4	32	F	Nodule (L)	20	—	—	—	Adenoma	20	PAC, K, BP
5	71	F	Nodule (L)	17	—	—	—	Adenoma	25	PAC, PRA, K, BP
6	59	M	Nodule (L)	11	—	—	—	Adenoma	10	PAC, BP
7	60	F	Nodule (R)	21	—	—	—	Adenoma	20	PAC, K
8	72	M	Nodule (R)	22	—	—	—	Adenoma	20	PAC, PRA, K, BP
9	56	F	Nodule (L)	17	—	—	—	Adenoma	17	PAC, K, BP
SPECT/CT group (n = 6)
10	55	F	Normal	—	N	R	R	Micronodule	0.8	PAC, K, BP
11	48	F	Nodule (L)	17	L	L	L	Adenoma	17	PAC, PRA, K, BP
12^†	57	M	Enlarge (L)	9 (in thickness)	N	L	L	Focal nodular hyperplasia	6	PAC, PRA, K, BP
13	56	M	Nodule (L)	12	N	L	L	Adenoma	10	PAC, BP
14	39	M	Nodule (R)	14	N	R	R	Adenoma	12	PAC, K, BP
15^†	27	F	Normal	—	Faint	Bil	Bil	—^#	—^#	PAC, BP

Abbreviations: CT: computed tomography; L: left; R: right; Bil: bilateral; other abbreviations are the same as Table 1.
^†Patients 12 and 15 had stages 3 and 4 chronic kidney disease with serum creatinine level of 2.2 and 2.5 mg/dL, respectively.
^#Patient 15 did not undergo adrenalectomy because of bilateral adrenal hyperplasia.